Your browser doesn't support javascript.
loading
JNK pathway plays a critical role for expansion of human colorectal cancer in the context of BRG1 suppression.
Yoshikawa, Takaaki; Fukuda, Akihisa; Omatsu, Mayuki; Namikawa, Mio; Sono, Makoto; Fukunaga, Yuichi; Masuda, Tomonori; Araki, Osamu; Nagao, Munemasa; Ogawa, Satoshi; Masuo, Kenji; Goto, Norihiro; Hiramatsu, Yukiko; Muta, Yu; Tsuda, Motoyuki; Maruno, Takahisa; Nakanishi, Yuki; Kawada, Kenji; Takaishi, Shigeo; Seno, Hiroshi.
Affiliation
  • Yoshikawa T; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Fukuda A; Department of Gastroenterology and Hepatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
  • Omatsu M; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Namikawa M; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Sono M; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Fukunaga Y; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Masuda T; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Araki O; Department of Drug Discovery Medicine, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Nagao M; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Ogawa S; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Masuo K; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Goto N; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Hiramatsu Y; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Muta Y; Laboratory for Malignancy Control Research (DSK Project), Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Tsuda M; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Maruno T; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Nakanishi Y; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Kawada K; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Takaishi S; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Seno H; Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Cancer Sci ; 113(10): 3417-3427, 2022 Oct.
Article in En | MEDLINE | ID: mdl-35924439
ABSTRACT
Tumor stem cells (TSCs), capable of self-renewal and continuous production of progeny cells, could be potential therapeutic targets. We have recently reported that chromatin remodeling regulator Brg1 is required for maintenance of murine intestinal TSCs and stemness feature of human colorectal cancer (CRC) cells by inhibiting apoptosis. However, it is still unclear how BRG1 suppression changes the underlying intracellular mechanisms of human CRC cells. We found that Brg1 suppression resulted in upregulation of the JNK signaling pathway in human CRC cells and murine intestinal TSCs. Simultaneous suppression of BRG1 and the JNK pathway, either by pharmacological inhibition or silencing of c-JUN, resulted in even stronger inhibition of the expansion of human CRC cells compared to Brg1 suppression alone. Consistently, high c-JUN expression correlated with worse prognosis for survival in human CRC patients with low BRG1 expression. Therefore, the JNK pathway plays a critical role for expansion and stemness of human CRC cells in the context of BRG1 suppression, and thus a combined blockade of BRG1 and the JNK pathway could be a novel therapeutic approach against human CRC.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / MAP Kinase Signaling System Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Main subject: Colorectal Neoplasms / MAP Kinase Signaling System Type of study: Prognostic_studies Limits: Animals / Humans Language: En Year: 2022 Type: Article